Clinical trial
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg…
NCT00313170 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00313170 |
|---|---|
| Title | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg |
| Official title | Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy |
| Acronym | FINDER II |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer, Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 144 |
| Start date | May 30, 2006 |
| Primary completion | Jun 13, 2008 |
| Completion | Mar 13, 2019 |
| First posted | Apr 12, 2006 |
| Last update posted | Jan 6, 2020 |
| Countries | Belgium, Canada, Czechia, France, Hungary, Poland, Romania, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: